Skip to main content
Year archive

Shionogi & Co.,Ltd. — 2026 filings

All 26 regulatory filings released by Shionogi & Co.,Ltd. (4507) in 2026, sourced directly from the official regulator.

26 Filings
2026 Period
2026 filings (26)
Filing Released Lang
臨時報告書
Declaration of Voting Results & Voting Rights Announcements
2026-06-25 Japanese
譲渡制限付株式報酬としての自己株式の処分について
Share Issue/Capital Change
2026-06-24 Japanese
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
Share Issue/Capital Change
2026-06-24 English
資本コストや株価を意識した経営の実現に向けた対応に関するお知らせ
Investor Presentation
2026-06-24 Japanese
Notice Regarding Actions to Achieve Management Conscious of Capital Costs and Stock Prices
Investor Presentation
2026-06-24 English
臨時報告書
Regulatory Filings
2026-06-24 Japanese
抗新型コロナウイルス（SARS-CoV-2）薬ゾコーバの国内における小児用法・用量の追加承認について
Regulatory Filings
2026-06-19 Japanese
Shionogi Announces Supplemental Approval in Japan for Pediatric Dosage and Administration of XOCOVA to Treat COVID-19
Regulatory Filings
2026-06-19 English
確認書
Regulatory Filings
2026-06-19 Japanese
有価証券報告書－第161期(2025/04/01－2026/03/31)
Annual Report FY 2026
2026-06-19 Japanese
新規抗真菌薬オロロフィムのグローバル第3相臨床試験（OASIS試験）における 良好な結果について（速報）
Regulatory Filings
2026-06-18 Japanese
Positive Topline Results from Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome Followed by SOC in Patients with Invasive Aspergillosis
Earnings Release Q1 2027
2026-06-18 English
(Corrections) Shionogi Announces FDA Approval of XOCOVA (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure
Regulatory Filings
2026-06-01 English
Shionogi Announces FDA Approval of XOCOVA (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure
Regulatory Filings
2026-06-01 English
抗新型コロナウイルス（SARS-CoV-2）薬 エンシトレルビル フマル酸の COVID-19 曝露後発症予防における米国FDAの承認について
Regulatory Filings
2026-06-01 Japanese
Notice Regarding Approval of Naldemedine for Opioid-Induced Constipation in China
Regulatory Filings
2026-05-29 English
オピオイド誘発性便秘症治療薬ナルデメジンの中国における新薬承認取得について
Regulatory Filings
2026-05-29 Japanese
Fiscal 2025 Financial Results
Investor Presentation
2026-05-12 English
Financial Results for FY2025 Supplement
Interim / Quarterly Report FY 2025
2026-05-12 English
Consolidated Financial Results for Fiscal Year 2025(IFRS)
Earnings Release FY 2026
2026-05-12 English
2026年３月期決算短信〔ＩＦＲＳ〕(連結)
Regulatory Filings
2026-05-12 Japanese
訂正臨時報告書
M&A Activity
2026-04-27 Japanese
当社の完全子会社である鳥居薬品株式会社の吸収合併（簡易合併・略式合併）に関するお知らせ
M&A Activity
2026-04-27 Japanese
2026年3月期 配当予想の修正（増配）に関するお知らせ
Notice of Dividend Amount
2026-04-27 Japanese
2026年3月期 配当予想の修正（増配）に関するお知らせ
Regulatory Filings
2026-04-27 Japanese
2026年3月期 第3四半期 決算短信〔ＩＦＲＳ〕（連結）
Regulatory Filings
2026-01-30 Japanese